1 of 1
Story summary
- The NHS began rolling out Mounjaro in June but faces criticism over funding issues.
- Access varies significantly, with less than half of England's commissioning bodies prescribing the drug.
- Only nine areas can fund treatment for 70% of eligible patients; others cover 25% or less.
- Experts highlight unclear prescribing rules, leaving many patients without necessary treatment.
- Current funding meets only 10% of the NHS's goal to treat 220,000 patients in three years.
- A price increase has caused panic buying and raised concerns about counterfeit drugs.
- Weight-related illnesses cost the UK economy £74 billion annually, with two-thirds of Britons overweight or obese.
